R&D and Commercialization of New Menus, Including Healthy and Nursing Care Foods
First written in FY2016. 25 of 28 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Achieved".
- FY2026AchievedAnnual report
「The company is also conducting R&D on menus and delivery methods for care and health foods, for which market expansion is expected, incorporating individually portioned ingredients and prepared foods that can be cooked easily and quickly, and is commercializing these products. Total R&D expenses for the fiscal year were ¥27 million.」
The wording has been changed to state that the company is commercializing care and health foods while continuing its R&D. R&D expenses for the fiscal year were ¥27 million. - FY2025RestatedAnnual report
「The company is also conducting R&D on menus and delivery methods for care and health foods, for which market expansion is expected, incorporating individually portioned ingredients and prepared foods that can be cooked easily and quickly, with a view to commercializing them. Total R&D expenses for the consolidated fiscal year were ¥26 million.」
The company continued its R&D policy aimed at commercializing care and health foods, with R&D expenses of ¥26 million for the fiscal year. - FY2025-H1AdvancedAnnual report
「As a new initiative, we began offering the “Nutritionally Controlled Bento” at all sales offices, whereas it had previously been sold only in certain regions. This enables customers to choose products with nutritional values tailored to their health needs, including salt, protein and calorie content. We have also begun considering ways to use the product in B2B operations and across various sales channels, rather than limiting it to the B2C business.」
The “Nutritionally Controlled Bento,” previously sold in certain regions, is now available at all sales offices. The company has also begun considering its use in the B2B business and across various sales channels for health-oriented products. - FY2024RestatedAnnual report
「The company is conducting research and development into menus and delivery methods for care foods and healthy foods, whose markets are expected to expand, incorporating ingredients and prepared foods that can be prepared easily and quickly for individual servings, with the aim of commercializing the business. Total research and development expenses for the current consolidated fiscal year were ¥22 million.」
The company continued R&D aimed at commercializing care and health foods, with R&D expenses of ¥22 million for the fiscal year. - FY2023RestatedAnnual report
「The company is conducting research and development into menus and delivery methods for care foods and healthy foods, whose markets are expected to expand, incorporating ingredients and prepared foods that can be prepared easily and quickly for individual servings, with the aim of commercializing the business. Total research and development expenses for the current consolidated fiscal year were ¥18 million.」
The company continued R&D aimed at commercializing care and health foods, with R&D expenses of ¥18 million for the fiscal year. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the consolidated fiscal year were ¥15 million.」
The company has continued its R&D activities and disclosed R&D expenses of ¥15 million for the cumulative third quarter of the consolidated fiscal year. - FY2023-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥10 million.」
The company has continued R&D activities aimed at commercializing care and health foods, and disclosed R&D expenses of ¥10 million for the cumulative second quarter period. - FY2023-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥6 million.」
The company continued research and development activities aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥6 million for the cumulative period through the first quarter. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥18 million.」
The company has continued R&D aimed at commercializing care and health foods, and disclosed R&D expenses of ¥18 million for the cumulative third quarter period. - FY2022-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥5 million.」
The company continued its research and development activities and disclosed research and development expenses of ¥5 million for the cumulative period through the first quarter of the current consolidated fiscal year. - FY2021RestatedAnnual report
「The company is conducting research and development into menus and delivery methods for care foods and healthy foods, whose markets are expected to expand, incorporating ingredients and prepared foods that can be prepared easily and quickly for individual servings, with the aim of commercializing the business. Total research and development expenses for the current consolidated fiscal year were ¥18 million.」
The company continued research and development aimed at commercializing care foods and healthy foods, and disclosed research and development expenses of ¥18 million for the current fiscal year. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥14 million.」
The company continued research and development activities aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥14 million for the cumulative period through the third quarter of the current consolidated fiscal year. - FY2021-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥10 million.」
The company continued research and development activities aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥10 million for the cumulative period through the second quarter of the current consolidated fiscal year. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥5 million.」
The company continued its research and development activities and disclosed research and development expenses of ¥5 million for the cumulative period through the first quarter of the current consolidated fiscal year. - FY2020-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥19 million.」
The company continued research and development activities aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥19 million for the cumulative period through the third quarter. - FY2020-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥5 million.」
The company continued research and development activities aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥5 million for the cumulative period through the first quarter. - FY2019RestatedAnnual report
「The company is conducting research and development into menus and delivery methods for care foods and healthy foods, whose markets are expected to expand, incorporating ingredients and prepared foods that can be prepared easily and quickly for individual servings, with the aim of commercializing the business. Total research and development expenses for the current consolidated fiscal year were ¥22 million.」
The company continued research and development aimed at commercializing care foods and healthy foods, and disclosed research and development expenses of ¥22 million for the current consolidated fiscal year. - FY2019-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥17 million.」
The company continued research and development activities aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥17 million for the cumulative period through the third quarter. - FY2019-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥11 million.」
The company continued research and development activities aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥11 million for the cumulative period through the second quarter. - FY2019-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥6 million.」
The company continued research and development activities aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥6 million for the cumulative period through the first quarter. - FY2018-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥22 million.」
The company continued its research and development activities and disclosed research and development expenses of ¥22 million for the cumulative period through the third quarter of the current consolidated fiscal year. - FY2018-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥13 million.」
The company continued research and development aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥13 million for the cumulative period through the second quarter. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥7 million.」
The company continued research and development aimed at commercializing care foods, healthy foods and other products, and disclosed research and development expenses of ¥7 million for the cumulative period through the first quarter. - FY2017RestatedAnnual report
「The company is conducting research and development into menus and delivery methods for care foods and healthy foods, whose markets are expected to expand, incorporating ingredients and prepared foods that can be prepared easily and quickly for individual servings, with the aim of commercializing the business. Total research and development expenses for the current consolidated fiscal year were ¥28 million.」
The company continued research and development aimed at commercializing care foods and healthy foods, with research and development expenses of ¥28 million for the current consolidated fiscal year. - FY2017-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period were ¥22 million.」
The company continued its research and development activities and disclosed research and development expenses of ¥22 million for the cumulative period through the third quarter. - FY2017-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period were ¥14 million.」
The company continued its research and development activities and disclosed research and development expenses of ¥14 million for the cumulative period through the second quarter. - FY2017-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥7 million.」
The company continued its research and development activities and disclosed research and development expenses of ¥7 million for the quarter. - FY2016First statedAnnual report
「The company is conducting research and development into menus and delivery methods for care foods and healthy foods, whose markets are expected to expand, incorporating ingredients and prepared foods that can be prepared easily and quickly for individual servings, with the aim of commercializing the business.」
The company aims to commercialize care foods and healthy foods centered on individual servings, short preparation times and prepared foods.